Rheumatoid Arthritis News

PHILADELPHIA — An early switch from adalimumab to upadacitinib due to non-response demonstrated clinical improvement among patients with rheumatoid arthritis, according to data presented at ACR Convergence 2022.

In this episode of Meeting Mic, we bring you the highlights and insights from the ACR Convergence 2022, as well as Healio’s top headlines from the meeting.

PHILADELPHIA — Among patients with rheumatoid arthritis who had an inadequate response or intolerance to TNF inhibitors, upadacitinib demonstrated clinically meaningful and improved efficacy over 24 weeks, according to a post-hoc analysis.

PHILADELPHIA — Patients with rheumatoid arthritis frequently switched between JAK inhibitors in Australia, according to a presentation at ACR Convergence 2022.

PHILADELPHIA — There is “no clear increased risk” for major adverse cardiovascular events associated with tofacitinib, according to a post-hoc analysis of the ORAL Surveillance trial presented at ACR Convergence 2022.

PHILADELPHIA — A daily glucocorticoid dose higher than 2.5 mg may lead to irreversible bone mineral density loss regardless of intervention with osteoporosis medications, according to data presented at ACR Convergence 2022.

New guidance from the American College of Rheumatology strongly recommends that patients with rheumatoid arthritis engage in physical exercise when possible.

The ongoing development of splenic nerve stimulation has continued to provide a window into the potential future of bioelectronics in medicine, according to Kristoffer Famm, PhD, president of Galvani Bioelectronics, based in the U.K.

PHILADELPHIA — A novel therapy targeting human programmed cell death protein-1 showed efficacy in rheumatoid arthritis with an attractive safety profile, according to a speaker at ACR Convergence 2022.

PHILADELPHIA — Patients who switched from one infliximab biosimilar to another experienced comparable treatment retention rates, according to data presented at ACR Convergence 2022.